<DOC>
	<DOCNO>NCT00756067</DOCNO>
	<brief_summary>The purpose observer-blind study evaluate safety , reactogenicity immunogenicity pneumococcal vaccine elderly . Subjects vaccinate twice interval two month .</brief_summary>
	<brief_title>Evaluation Pneumococcal Vaccine Formulations Elderly</brief_title>
	<detailed_description />
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . Male female subject , include , 65 85 year old time first vaccination , relatively stable health . Written inform consent obtain subject . Previous vaccination Streptococcus pneumoniae ( licensed vaccine investigational candidate vaccine ) . Vaccination diphtheria/tetanus toxoid within one month precede first dose study vaccine . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period participation another pharmaceutical/vaccine study . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/administration vaccine foreseen study protocol within 30 day first dose study vaccine , exception influenza vaccine administer least 7 day precede least 7 day follow vaccine dose . Administration immunoglobulins and/or blood product within last 3 month . Bacterial pneumonia within 3 year prior 1st vaccination . Invasive pneumococcal disease ( I.P.D ) within 3 year prior 1st vaccination . History thrombocytopenia bleed disorder . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . History reaction allergic disease likely exacerbate component vaccine . History administration experimental/licensed vaccine contain MPL QS21 . Current serious neurologic mental disorder . Inflammatory process know chronic active infection ( e.g . Hepatitis B , C ) . All past current malignancy ( exclude nonmelanic skin cancer ) lymphoproliferative disorder diagnose treat actively past 5 year . Acute disease time enrolment . Physical examination positive acrocyanosis , jaundice , splenomegaly Acute chronic , clinically significant anaemia , pulmonary , cardiovascular , hepatic renal functional abnormality , determine history , physical examination laboratory screen test discretion investigator . Laboratory evidence haematological abnormality . Laboratory evidence biochemical abnormality . History chronic alcohol consumption and/or drug abuse . Other condition principal investigator judge may interfere study finding .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>pneumococcal vaccine</keyword>
</DOC>